Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice
With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to co...
Gespeichert in:
| Veröffentlicht in: | Journal of controlled release 2013-12, Vol.172 (3), p.1045-1064 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1064 |
|---|---|
| container_issue | 3 |
| container_start_page | 1045 |
| container_title | Journal of controlled release |
| container_volume | 172 |
| creator | Stirland, Darren Lars Nichols, Joseph W. Miura, Seiji Bae, You Han |
| description | With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
[Display omitted] |
| doi_str_mv | 10.1016/j.jconrel.2013.09.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3889175</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168365913008146</els_id><sourcerecordid>1516750401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c590t-5b2e6d1dc17d24f3c463b0e4a080b591b1e6d0928f54137a77e643b5f7b8e05f3</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EotuFRwB85JIwju045gCqKgpIRRygZ8txJrtesnGwk6369rjabQUnTrY03_wez0fIKwYlA1a_25U7F8aIQ1kB4yXoEqr6CVmxRvFCaC2fklXmmoLXUp-R85R2ACC5UM_JWSVA18DEivz65seOzlukGzu9pxc0LfGAdzT0dBtuqbOjw0i7uGzyPUaPMVEbMWPJ4TT7dkA6h4cA2uJ8izjSiAltdFtqc_oUrZu9wxfkWW-HhC9P55rcXH36efmluP7--evlxXXhpIa5kG2Fdcc6x1RXiZ47UfMWUFhooJWatSyXQVdNLwXjyiqFteCt7FXbIMier8mHY-60tHvsHI5ztIOZot_beGeC9ebfyui3ZhMOhjeNZkrmgLengBh-L5hms_f5u8NgRwxLMkyyWkkQefFrIo-oiyGliP3jMwzMvSizMydR5l6UAW2yqNz3-u8ZH7sezGTgzRHobTB2E30yNz9yggRgSnGpM_HxSGDe5SGbMcl5zL46H9HNpgv-P0P8AVZgsck</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1516750401</pqid></control><display><type>article</type><title>Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Stirland, Darren Lars ; Nichols, Joseph W. ; Miura, Seiji ; Bae, You Han</creator><creatorcontrib>Stirland, Darren Lars ; Nichols, Joseph W. ; Miura, Seiji ; Bae, You Han</creatorcontrib><description>With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
[Display omitted]</description><identifier>ISSN: 0168-3659</identifier><identifier>EISSN: 1873-4995</identifier><identifier>DOI: 10.1016/j.jconrel.2013.09.026</identifier><identifier>PMID: 24096014</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Animals ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - pharmacokinetics ; Antineoplastic Agents - therapeutic use ; Cancer therapy ; Clinical translation ; Clinical Trials as Topic ; Drug carrier ; drug carriers ; Drug Carriers - chemistry ; Drug Carriers - metabolism ; Drug Carriers - toxicity ; Drug delivery ; Drug Delivery Systems - methods ; Drug Evaluation, Preclinical ; drug therapy ; drugs ; Humans ; Models, Molecular ; Nanomedicine ; nanoparticles ; Nanostructures - chemistry ; Nanostructures - toxicity ; neoplasms ; Neoplasms - drug therapy ; pharmacokinetics ; surveys ; toxicity</subject><ispartof>Journal of controlled release, 2013-12, Vol.172 (3), p.1045-1064</ispartof><rights>2013 Elsevier B.V.</rights><rights>2013 Elsevier B.V. All rights reserved.</rights><rights>2013 Elsevier B.V. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c590t-5b2e6d1dc17d24f3c463b0e4a080b591b1e6d0928f54137a77e643b5f7b8e05f3</citedby><cites>FETCH-LOGICAL-c590t-5b2e6d1dc17d24f3c463b0e4a080b591b1e6d0928f54137a77e643b5f7b8e05f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jconrel.2013.09.026$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,782,786,887,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24096014$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stirland, Darren Lars</creatorcontrib><creatorcontrib>Nichols, Joseph W.</creatorcontrib><creatorcontrib>Miura, Seiji</creatorcontrib><creatorcontrib>Bae, You Han</creatorcontrib><title>Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice</title><title>Journal of controlled release</title><addtitle>J Control Release</addtitle><description>With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
[Display omitted]</description><subject>Animals</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - pharmacokinetics</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cancer therapy</subject><subject>Clinical translation</subject><subject>Clinical Trials as Topic</subject><subject>Drug carrier</subject><subject>drug carriers</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Carriers - metabolism</subject><subject>Drug Carriers - toxicity</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Evaluation, Preclinical</subject><subject>drug therapy</subject><subject>drugs</subject><subject>Humans</subject><subject>Models, Molecular</subject><subject>Nanomedicine</subject><subject>nanoparticles</subject><subject>Nanostructures - chemistry</subject><subject>Nanostructures - toxicity</subject><subject>neoplasms</subject><subject>Neoplasms - drug therapy</subject><subject>pharmacokinetics</subject><subject>surveys</subject><subject>toxicity</subject><issn>0168-3659</issn><issn>1873-4995</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi0EotuFRwB85JIwju045gCqKgpIRRygZ8txJrtesnGwk6369rjabQUnTrY03_wez0fIKwYlA1a_25U7F8aIQ1kB4yXoEqr6CVmxRvFCaC2fklXmmoLXUp-R85R2ACC5UM_JWSVA18DEivz65seOzlukGzu9pxc0LfGAdzT0dBtuqbOjw0i7uGzyPUaPMVEbMWPJ4TT7dkA6h4cA2uJ8izjSiAltdFtqc_oUrZu9wxfkWW-HhC9P55rcXH36efmluP7--evlxXXhpIa5kG2Fdcc6x1RXiZ47UfMWUFhooJWatSyXQVdNLwXjyiqFteCt7FXbIMier8mHY-60tHvsHI5ztIOZot_beGeC9ebfyui3ZhMOhjeNZkrmgLengBh-L5hms_f5u8NgRwxLMkyyWkkQefFrIo-oiyGliP3jMwzMvSizMydR5l6UAW2yqNz3-u8ZH7sezGTgzRHobTB2E30yNz9yggRgSnGpM_HxSGDe5SGbMcl5zL46H9HNpgv-P0P8AVZgsck</recordid><startdate>20131228</startdate><enddate>20131228</enddate><creator>Stirland, Darren Lars</creator><creator>Nichols, Joseph W.</creator><creator>Miura, Seiji</creator><creator>Bae, You Han</creator><general>Elsevier B.V</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope></search><sort><creationdate>20131228</creationdate><title>Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice</title><author>Stirland, Darren Lars ; Nichols, Joseph W. ; Miura, Seiji ; Bae, You Han</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c590t-5b2e6d1dc17d24f3c463b0e4a080b591b1e6d0928f54137a77e643b5f7b8e05f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - pharmacokinetics</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cancer therapy</topic><topic>Clinical translation</topic><topic>Clinical Trials as Topic</topic><topic>Drug carrier</topic><topic>drug carriers</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Carriers - metabolism</topic><topic>Drug Carriers - toxicity</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Evaluation, Preclinical</topic><topic>drug therapy</topic><topic>drugs</topic><topic>Humans</topic><topic>Models, Molecular</topic><topic>Nanomedicine</topic><topic>nanoparticles</topic><topic>Nanostructures - chemistry</topic><topic>Nanostructures - toxicity</topic><topic>neoplasms</topic><topic>Neoplasms - drug therapy</topic><topic>pharmacokinetics</topic><topic>surveys</topic><topic>toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stirland, Darren Lars</creatorcontrib><creatorcontrib>Nichols, Joseph W.</creatorcontrib><creatorcontrib>Miura, Seiji</creatorcontrib><creatorcontrib>Bae, You Han</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of controlled release</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stirland, Darren Lars</au><au>Nichols, Joseph W.</au><au>Miura, Seiji</au><au>Bae, You Han</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice</atitle><jtitle>Journal of controlled release</jtitle><addtitle>J Control Release</addtitle><date>2013-12-28</date><risdate>2013</risdate><volume>172</volume><issue>3</issue><spage>1045</spage><epage>1064</epage><pages>1045-1064</pages><issn>0168-3659</issn><eissn>1873-4995</eissn><abstract>With countless research papers using preclinical models and showing the superiority of nanoparticle design over current drug therapies used to treat cancers, it is surprising how deficient the translation of these nano-sized drug carriers into the clinical setting is. This review article seeks to compare the preclinical and clinical results for Doxil®, PK1, Abraxane®, Genexol-PM®, Xyotax™, NC-6004, Mylotarg®, PK2, and CALAA-01. While not comprehensive, it covers nano-sized drug carriers designed to improve the efficacy of common drugs used in chemotherapy. While not always available or comparable, effort was made to compare the pharmacokinetics, toxicity, and efficacy between the animal and human studies. Discussion is provided to suggest what might be causing the gap. Finally, suggestions and encouragement are dispensed for the potential that nano-sized drug carriers hold.
[Display omitted]</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>24096014</pmid><doi>10.1016/j.jconrel.2013.09.026</doi><tpages>20</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-3659 |
| ispartof | Journal of controlled release, 2013-12, Vol.172 (3), p.1045-1064 |
| issn | 0168-3659 1873-4995 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3889175 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Animals Antineoplastic Agents - administration & dosage Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Cancer therapy Clinical translation Clinical Trials as Topic Drug carrier drug carriers Drug Carriers - chemistry Drug Carriers - metabolism Drug Carriers - toxicity Drug delivery Drug Delivery Systems - methods Drug Evaluation, Preclinical drug therapy drugs Humans Models, Molecular Nanomedicine nanoparticles Nanostructures - chemistry Nanostructures - toxicity neoplasms Neoplasms - drug therapy pharmacokinetics surveys toxicity |
| title | Mind the gap: A survey of how cancer drug carriers are susceptible to the gap between research and practice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T22%3A20%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mind%20the%20gap:%20A%20survey%20of%20how%20cancer%20drug%20carriers%20are%20susceptible%20to%20the%20gap%20between%20research%20and%20practice&rft.jtitle=Journal%20of%20controlled%20release&rft.au=Stirland,%20Darren%20Lars&rft.date=2013-12-28&rft.volume=172&rft.issue=3&rft.spage=1045&rft.epage=1064&rft.pages=1045-1064&rft.issn=0168-3659&rft.eissn=1873-4995&rft_id=info:doi/10.1016/j.jconrel.2013.09.026&rft_dat=%3Cproquest_pubme%3E1516750401%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1516750401&rft_id=info:pmid/24096014&rft_els_id=S0168365913008146&rfr_iscdi=true |